ilaprazole has been researched along with s 1743 in 10 studies
| Studies (ilaprazole) | Trials (ilaprazole) | Recent Studies (post-2010) (ilaprazole) | Studies (s 1743) | Trials (s 1743) | Recent Studies (post-2010) (s 1743) |
|---|---|---|---|---|---|
| 53 | 24 | 42 | 1,228 | 569 | 704 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, KH; Kim, DY; Kukulka, M; Lee, JY; Park, HL; Park, SH; Shin, JS; Wu, JT | 1 |
| Kim, EH; Kim, HY; Lee, SK; Park, CH; Roh, YH | 1 |
| Hu, H; Lin, S; Qin, X; Wang, L; Xia, J; Xue, Y; Zhou, L | 2 |
| Jin, Y; Pan, J; Wang, Q; Yao, D; Yue, M; Zhang, G; Zhang, S | 1 |
| Hou, X; Hu, H; Jiang, J; Liu, F; Liu, X; Ou, N; Qin, X; Shao, F; Wang, H; Xu, W | 1 |
| Kan, LD; Li, LC; Wu, CY; Ying, J; Yu, ZW | 1 |
| Chen, F; Fang, B; He, X; Wang, S | 1 |
| Cui, Y; Han, Z; Hou, X; Jiang, X; Jin, Z; Li, C; Li, Q; Qiu, W; Shen, T; You, J | 1 |
| Chen, J; Deng, W; Xie, Z; Yang, S | 1 |
2 review(s) available for ilaprazole and s 1743
| Article | Year |
|---|---|
The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dexlansoprazole; Esomeprazole; Humans; Lansoprazole; Magnesium; Odds Ratio; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Risk Factors; Treatment Outcome | 2014 |
Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysis.
Topics: Abdominal Injuries; Esomeprazole; Esophagitis, Peptic; Humans; Network Meta-Analysis; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole | 2022 |
5 trial(s) available for ilaprazole and s 1743
| Article | Year |
|---|---|
The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Cross-Over Studies; Esomeprazole; Female; Gastrins; Healthy Volunteers; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Proton Pump Inhibitors | 2014 |
A Randomized, Double-blind, Active-Controlled, Multi-center Study of Ilaprazole in the Treatment of Reflux Esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Double-Blind Method; Esomeprazole; Esophagitis, Peptic; Female; Heartburn; Humans; Male; Middle Aged; Proton Pump Inhibitors | 2016 |
A randomized, double blind, controlled, multi center study of Ilaparazole in the treatment of reflux esophagitis-Phase III clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Double-Blind Method; Drug Monitoring; Esomeprazole; Esophagitis, Peptic; Female; Gastroscopy; Humans; Male; Middle Aged; Proton Pump Inhibitors; Symptom Assessment; Treatment Outcome | 2018 |
Comparison of efficacy and safety of ilaprazole and esomeprazole both in initial treatment regimen and retreatment regimen of Helicobacter pylori infection in chronic gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Chronic Disease; Drug Therapy, Combination; Esomeprazole; Female; Furazolidone; Gastritis; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Minocycline; Prospective Studies; Proton Pump Inhibitors; Retreatment; Treatment Failure; Treatment Outcome | 2019 |
Efficacy, safety and pharmacokinetics of ilaprazole infusion in healthy subjects and patients with esomeprazole as positive control.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; China; Duodenal Ulcer; Duodenoscopy; Esomeprazole; Female; Gastric Acid; Gastric Acidity Determination; Healthy Volunteers; Humans; Infusions, Intravenous; Male; Middle Aged; Proton Pump Inhibitors; Treatment Outcome; Young Adult | 2019 |
3 other study(ies) available for ilaprazole and s 1743
| Article | Year |
|---|---|
The status of proton pump inhibitor use: a prescription survey of 45 hospitals in China.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; China; Comorbidity; Esomeprazole; Female; Health Care Surveys; Hospitals; Humans; Inappropriate Prescribing; Lansoprazole; Male; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2019 |
Simultaneous Quantitative Analysis of Six Proton-Pump Inhibitors with a Single Marker and Evaluation of Stability of Investigated Drugs in Polypropylene Syringes for Continuous Infusion Use.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chromatography, High Pressure Liquid; Drugs, Investigational; Esomeprazole; Humans; Lansoprazole; Molecular Structure; Omeprazole; Pantoprazole; Polypropylenes; Proton Pump Inhibitors; Rabeprazole | 2020 |
An analysis of the biopharmaceutical behaviour of proton pump inhibitors with different physicochemical properties.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Absorption, Physicochemical; Adsorption; Animals; Biological Products; Chemical Phenomena; China; Esomeprazole; Female; Ileum; Intestinal Absorption; Jejunum; Male; Proton Pump Inhibitors; Rabeprazole; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry; Tissue Distribution | 2021 |